Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...
Drug
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...
BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...
Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...
Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...
Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE:...
Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...
ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors
Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...
Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...
CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the completion of 1,200 patient...
Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...
BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial
Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...
SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301
SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study
Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...